Fig. 6. The potentiation and inactivation of polycystic kidney disease 2-like-1 (PKD2L1) (L593A) with over-expression of calmodulin (CaM) under 16 nM and 100 nM intracellular free calcium concentrations. (A) A full current trace of PKD2L1 (L593A) (gray) and the mutant co-expressed with CaM (blue) under 16 nM free Ca²⁺. (B) A full current trace of PKD2L1 (L593A) (gray) and the mutant co-expressed with CaM (red) under 100 nM free Ca²⁺. (C) A summarized peak current amplitude of PKD2L1 (L593A) and the mutant co-expressed with CaM under 16 nM and 100 nM free Ca²⁺ (n = 4). (D) A summarized peak time of PKD2L1 (L593A) and the mutant co-expressed with CaM under 16 nM and 100 nM free Ca²⁺ (n = 4). *p < 0.05.

Korean J Physiol Pharmacol 2020;24:277-286 https://doi.org/10.4196/kjpp.2020.24.3.277

© Korean J Physiol Pharmacol